Analysts polled by Capital IQ expected a $1.17 loss per share for the year.
Revenue fell to $69.6 million from $100.4 million a year ago. The Street estimated $75.42 million.
Looking ahead, the clinical-stage drugmaker expects to start a phase 1 study of CX-904 in advanced solid tumors in the first half of this year, and also to continue patient enrollment in the expansion phase of the mid-stage study of CX-2029 and provide more data in the second half of 2022.
Price: 3.9, Change: +0.36, Percent Change: +10.17
|Barclays Starts Hilton Grand Vacations at Overweight...|
|Barclays Starts Royal Caribbean Cruises at Overweigh...|
|--Barclays Starts Norwegian Cruise Line Holdings at ...|
|DA Davidson Cuts Nike's Price Target to $155 From $1...|
|Crude Oil Prices Rally as US Crude Inventories Drop ...|